Nektar Therapeutics
NASDAQ: NKTRSan Francisco, US · Founded 1990 · Delaware corporation · 676 employees on LinkedIn · 2 known investors
Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
Founders & leadership
HW
Howard W. RobinExecutive
GM
Gil M. LabrucherieinChief Operating Officer and Chief Financial Officer2016–2022
MH
Maninder HorainChief Technical Operation Officer and SVP, Pharmaceutical Development & Manufacturing2010–2019
SK
Stephen K. DobersteinExecutive
JN
John NicholsonExecutive
JB
Jillian B. ThomsenExecutive
Board
LL
Lutz LingnauBoard director
RW
Roy WhitfieldBoard director
CA
Christopher A. KueblerBoard director
DL
Dennis L. WingerBoard director
JR
Jeff R. AjerBoard director
RS
R. Scott GreerBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$880M disclosed across 2 rounds · 2018–2024
▶$30MraisedMar 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$30MraisedMar 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roy A WhitfieldDirector
- Mark A WilsonExecutive Officer
- Sandra GardinerExecutive Officer
- Jeffrey R AjerDirector
- Howard W RobinExecutive Officer, Director
- Diana M BrainardDirector
- Robert B ChessDirector
- R. Scott GreerDirector
- Jonathan ZalevskyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850MraisedApr 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$850MraisedApr 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lutz LingnauDirector
- Howard W. RobinExecutive Officer, Director
- Gil M. LabrucherieExecutive Officer
- Maninder HoraExecutive Officer
- Stephen K. DobersteinExecutive Officer
- John NicholsonExecutive Officer
- Roy WhitfieldDirector
- Jillian B. ThomsenExecutive Officer
- Christopher A. KueblerDirector
- Dennis L. WingerDirector
- Jeff R. AjerDirector
- R. Scott GreerDirector
- Robert ChessDirector
- Offering amount
- $850M
- Amount sold
- $850M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Nektar Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlap
Medscape65 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Seeking Alpha53 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Nektar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - Simply Wall St Newssimplywall.st · Aug 2026
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launchfinance.yahoo.com · Aug 2026
Nektar Therapeutics posts $85.5M first-half loss | NKTR Quarterly Report (10-Q)stocktitan.net · Aug 2026
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm - AOLaol.com · Aug 2026Frequently asked questions
- What does Nektar Therapeutics do?
- Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
- Who are Nektar Therapeutics's investors?
- Nektar Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA).
- How much funding has Nektar Therapeutics raised?
- Nektar Therapeutics has disclosed $880M raised across 2 rounds.
- Where is Nektar Therapeutics headquartered?
- Nektar Therapeutics is headquartered in San Francisco, US.